Tilray Brands, Inc. - Common Stock (TLRY)

Shares of cannabis company Tilray Brands (NASDAQ:TLRY) jumped 24.9% in the morning session after the company reported third-quarter financial results that topped analyst expectations. 

Tilray surprised marijuana investors once today. Can it do it again?

Tilray stock surges after Q1 earnings beat estimates with break-even results, higher revenue, and improved balance sheet strength.

The session on Thursday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Cannabis company Tilray Brands (NASDAQ:TLRY) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 4.7% year on year to $209.5 million. Its non-GAAP loss of $0 per share increased from -$0.04 in the same quarter last year.

Tilray Brands returns to profitability in Q1 fiscal 2026, posting record revenue and a positive EPS, driving a strong pre-market stock surge.

The company said that it reduced its total outstanding debt by $7.7 million in the three months in a bid to strengthen its balance sheet.

The potential for cannabis reform has made investors bullish on the industry in recent weeks.

Cannabis company Tilray Brands (NASDAQ:TLRY) will be reporting earnings this Thursday before the bell. Here’s what to look for.

The case for de facto marijuana legalization is growing, albeit slowly.

One marijuana industry insider says Monday's Truth Social video is a "trial balloon" testing support for marijuana legalization.

The cannabis market reacted big time to Trump's re-posting of a pro-CBD video that highlighted CBD’s potential to reduce aging-related ailments and replace costly pharmaceuticals. In addition, Tilray announced significant international expansion.

Tilray Brands reports earnings next week, which could determine whether its recent rally holds up.

Stocks shrugged off the government shutdown by hitting record highs; the focus now turns to the upcoming earnings season, which will likely lead stocks higher.

President Trump appeared to endorse CBD and having Medicare cover it, while cannabis de-scheduling remains a possibility.

The stock remains significantly down from its all-time highs.

Looking back on beverages, alcohol, and tobacco stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Coca-Cola (NYSE:KO) and its peers.

Surprise! Tilray is actually a much bigger deal in Germany than in the U.S.

President Trump's social media feed put the markets in a frenzy.